Panitumumab, a fully human monoclonal IgG2 antibody, first gained FDA approval in 2006 for the treatment of EGFR+ metastatic CRC following fluoropyrimidine, oxaliplatin, and irinotecan treatment failure [121]. This evidence concerns the gene EGFR and colorectal carcinoma.